{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T05:18:55Z","timestamp":1740806335954,"version":"3.38.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","elsevier.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.remnie.2024.500064","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T01:06:09Z","timestamp":1727485569000},"page":"500064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Response, complications and risk of leukemic transformation of phosphorus-32p treatment in philadelphia-negative chronic myeloproliferative syndromes"],"prefix":"10.1016","volume":"44","author":[{"given":"I.","family":"Tobalina Larrea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Cuetos Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mendizabal Abad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Montero de la Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Garc\u00eda Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.H.","family":"Portilla Quatrociocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Jim\u00e9nez Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.C.","family":"Menchaca Echevarria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.remnie.2024.500064_bib0005","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.remnie.2024.500064_bib0010","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms; critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol."},{"issue":"9","key":"10.1016\/j.remnie.2024.500064_bib0015","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia."},{"issue":"Suppl 1","key":"10.1016\/j.remnie.2024.500064_bib0020","first-page":"1551","article-title":"Epidemiological, diagnostic, therapeutic, and prognostic aspects of essential thrombocythemia in a retrospective study of the GIMMC group in two thousand patients","volume":"90","author":"Gugliotta","year":"1997","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.remnie.2024.500064_bib0025","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3322\/caac.20009","article-title":"Advances in understanding and management of myeloproliferative neoplasms","volume":"59","author":"Vannucchi","year":"2009","journal-title":"CA Cancer J Clin."},{"issue":"33","key":"10.1016\/j.remnie.2024.500064_bib0030","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.remnie.2024.500064_bib0035","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization\u2013essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.remnie.2024.500064_bib0040","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.remnie.2024.500064_bib0045","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1148\/35.1.51","article-title":"Nuclear physics and therapy: preliminary report of a new method for the treatment of leukemia and polycythemia","volume":"52","author":"Lawrence","year":"1940","journal-title":"Radiology."},{"key":"10.1016\/j.remnie.2024.500064_bib0050","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1038\/s41375-021-01401-3","article-title":"Polycythemia vera: historical oversights, diagnostic details, and therapeutic views","volume":"35","author":"Tefferi","year":"2021","journal-title":"Leukemia."},{"issue":"3","key":"10.1016\/j.remnie.2024.500064_bib0055","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/17474086.2019.1585239","article-title":"Developments in diagnosis and treatment of essential thrombocythemia","volume":"12","author":"Mora","year":"2019","journal-title":"Expert Rev Hematol."},{"key":"10.1016\/j.remnie.2024.500064_bib0060","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised Response Criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.remnie.2024.500064_bib0065","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1007\/s00259-007-0407-4","article-title":"EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases","volume":"34","author":"Tennvall","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2024.500064_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1034\/j.1600-0609.2000.9r119.x","article-title":"Treatment of the myeloproliferative disorders with P-32","volume":"65","author":"Berlin","year":"2000","journal-title":"Eur J Haematol."},{"key":"10.1016\/j.remnie.2024.500064_bib0075","first-page":"461","article-title":"Haematological complications in polycythaemia vera and thrombocythaemia patients treated with radiophosphorus (32P)","volume":"117","author":"Randi","year":"1990","journal-title":"Folia Haematol Int Mag Klin Morphol Blutforsch."},{"key":"10.1016\/j.remnie.2024.500064_bib0080","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.3390\/ijms20081839","article-title":"Blast transformation in myeloproliferative neoplasms: risk factors, biological findings, and targeted therapeutic options","volume":"20","author":"Iurlo","year":"2019","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.remnie.2024.500064_bib0085","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: An analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.remnie.2024.500064_bib0090","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","article-title":"The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms","volume":"112","author":"Tam","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.remnie.2024.500064_bib0095","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1600-0609.2008.01163.x","article-title":"AML transformation in 56 patients with Ph- MPD in two well defined populations","volume":"82","author":"Abdulkarim","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.remnie.2024.500064_bib0100","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","article-title":"3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups","volume":"94","author":"Szuber","year":"2019","journal-title":"Mayo Clin Proc."},{"issue":"6","key":"10.1016\/j.remnie.2024.500064_bib0105","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14740\/jh1042","article-title":"Acute myeloid leukemia following myeloproliferative neoplasms: a review of what we know, what we do not know, and emerging treatment strategies","volume":"11","author":"McKinnell","year":"2022","journal-title":"J Hematol."},{"key":"10.1016\/j.remnie.2024.500064_bib0110","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","article-title":"Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia."},{"issue":"1","key":"10.1016\/j.remnie.2024.500064_bib0115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasm","volume":"136","author":"Dunvar","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.remnie.2024.500064_bib0120","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2141.2005.05535.x","article-title":"Guidelines for the diagnosis, investigation and management of polycythemia\/erythrocytosis","volume":"130","author":"McMullin","year":"2005","journal-title":"Brit J Haematol."},{"key":"10.1016\/j.remnie.2024.500064_bib0125","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V89.7.2319","article-title":"Treatment of polycythemia vera: use of 32P alone or in combination withmaintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group","volume":"89","author":"Najean","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.remnie.2024.500064_bib0130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1600-0609.1995.tb01621.x","article-title":"Survival and risk of leukemia in polycythemia vera and essential thrombocythemia treated with oral radiophosphorus","volume":"54","author":"Brandt","year":"1995","journal-title":"Eur J Haematol."},{"key":"10.1016\/j.remnie.2024.500064_bib0135","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1259\/bjr.70.839.9536909","article-title":"Outcome of 259 patients with primary proliferative polycythaemia (PPP) and idiopathic thrombocythaemia (IT) treated in a regional nuclear medicine department with phosphorus-32--a 15 year review","volume":"70","author":"Balan","year":"1997","journal-title":"Brit J Radiol."},{"key":"10.1016\/j.remnie.2024.500064_bib0140","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.leukres.2010.07.031","article-title":"Myeloid blastic transformation of myeloproliferative neoplasms- a review of 112 cases","volume":"35","author":"Noor","year":"2011","journal-title":"Leuk Res."},{"key":"10.1016\/j.remnie.2024.500064_bib0145","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodisplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bjorkhokm","year":"2011","journal-title":"J Clin Oncol."},{"issue":"2","key":"10.1016\/j.remnie.2024.500064_bib0150","first-page":"83","article-title":"32P in the treatment of myeloproliferative disorders","volume":"85","author":"Lawless","year":"2016","journal-title":"Ulster Med J."},{"issue":"1","key":"10.1016\/j.remnie.2024.500064_bib0155","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1055\/a-1353-0941","article-title":"Combined chemotherapy and endoscopic ultrasound-guided intratumoral 32P implantation for locally advanced pancreatic adenocarcinoma: a pilot study","volume":"54","author":"Naidu","year":"2022","journal-title":"Endoscopy."}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808924000922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808924000922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T06:52:53Z","timestamp":1740725573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253808924000922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2253808924000922"],"URL":"https:\/\/doi.org\/10.1016\/j.remnie.2024.500064","relation":{},"ISSN":["2253-8089"],"issn-type":[{"type":"print","value":"2253-8089"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response, complications and risk of leukemic transformation of phosphorus-32p treatment in philadelphia-negative chronic myeloproliferative syndromes","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remnie.2024.500064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2024.500064","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"500064"}}